Epidemiology of Invasive Pneumococcal Disease in Southern California: Implications for the Design and Conduct of a Pneumococcal Conjugate Vaccine Efficacy Trial
Identifieur interne : 002099 ( Main/Exploration ); précédent : 002098; suivant : 002100Epidemiology of Invasive Pneumococcal Disease in Southern California: Implications for the Design and Conduct of a Pneumococcal Conjugate Vaccine Efficacy Trial
Auteurs : Kenneth M. Zangwill [États-Unis] ; Constance M. Vadheim [États-Unis] ; Ann M. Vannier [États-Unis] ; Leslie S. Hemenway [États-Unis] ; David P. Greenberg [États-Unis] ; Joel I. Ward [États-Unis]Source :
- Journal of Infectious Diseases [ 0022-1899 ] ; 1996-10.
Abstract
Population-based prospective surveillance of invasive pneumococcal disease was done in Southern California from 31 March 1992 to 1 April 1995; 814 cases were identified, for an incidence of 12.5/100,000 persons/year. The incidence among persons ≤2, ≤5, and ≥65 years of age was 145, 72, and 32/100,000, respectively. More than 95% of cases included bacteremia; incidence of meningitis was 0.8/100,000. Among children ≤2 years of age, 79% of isolates were obtained in the outpatient setting, compared with 16% of isolates among persons ≥15 years of age. Eighty percent of isolates were serotypes included in heptavalent pneumococcal conjugate vaccines currently being evaluated. Children ≤2 years of age were at highest risk of having an isolate resistant to penicillin. Among resistant isolates, high-level resistance increased from 4% to 21% over a 3-year period. Prospective epidemiologic data are needed to perform a protective efficacy trial of pneumococcal conjugate vaccines in infants, among whom most invasive pneumococcal disease is vaccine-preventable.
Url:
DOI: 10.1093/infdis/174.4.752
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Epidemiology of Invasive Pneumococcal Disease in Southern California: Implications for the Design and Conduct of a Pneumococcal Conjugate Vaccine Efficacy Trial</title><author><name sortKey="Zangwill, Kenneth M" sort="Zangwill, Kenneth M" uniqKey="Zangwill K" first="Kenneth M." last="Zangwill">Kenneth M. Zangwill</name></author><author><name sortKey="Vadheim, Constance M" sort="Vadheim, Constance M" uniqKey="Vadheim C" first="Constance M." last="Vadheim">Constance M. Vadheim</name></author><author><name sortKey="Vannier, Ann M" sort="Vannier, Ann M" uniqKey="Vannier A" first="Ann M." last="Vannier">Ann M. Vannier</name></author><author><name sortKey="Hemenway, Leslie S" sort="Hemenway, Leslie S" uniqKey="Hemenway L" first="Leslie S." last="Hemenway">Leslie S. Hemenway</name></author><author><name sortKey="Greenberg, David P" sort="Greenberg, David P" uniqKey="Greenberg D" first="David P." last="Greenberg">David P. Greenberg</name></author><author><name sortKey="Ward, Joel I" sort="Ward, Joel I" uniqKey="Ward J" first="Joel I." last="Ward">Joel I. Ward</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4F59A0F00B3C40BCEDAF488D3CE7AF21301D2DFF</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1093/infdis/174.4.752</idno><idno type="url">https://api.istex.fr/document/4F59A0F00B3C40BCEDAF488D3CE7AF21301D2DFF/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002095</idno><idno type="wicri:Area/Main/Curation">001D94</idno><idno type="wicri:Area/Main/Exploration">002099</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Epidemiology of Invasive Pneumococcal Disease in Southern California: Implications for the Design and Conduct of a Pneumococcal Conjugate Vaccine Efficacy Trial</title><author><name sortKey="Zangwill, Kenneth M" sort="Zangwill, Kenneth M" uniqKey="Zangwill K" first="Kenneth M." last="Zangwill">Kenneth M. Zangwill</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Harbor-UCLA Medical Center. UCLA Center for Vaccine Research, Torrance, and Kaiser Permanente Southern California Region, Regional Laboratories, North Hollywood</wicri:cityArea></affiliation></author><author><name sortKey="Vadheim, Constance M" sort="Vadheim, Constance M" uniqKey="Vadheim C" first="Constance M." last="Vadheim">Constance M. Vadheim</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Harbor-UCLA Medical Center. UCLA Center for Vaccine Research, Torrance, and Kaiser Permanente Southern California Region, Regional Laboratories, North Hollywood</wicri:cityArea></affiliation></author><author><name sortKey="Vannier, Ann M" sort="Vannier, Ann M" uniqKey="Vannier A" first="Ann M." last="Vannier">Ann M. Vannier</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Harbor-UCLA Medical Center. UCLA Center for Vaccine Research, Torrance, and Kaiser Permanente Southern California Region, Regional Laboratories, North Hollywood</wicri:cityArea></affiliation></author><author><name sortKey="Hemenway, Leslie S" sort="Hemenway, Leslie S" uniqKey="Hemenway L" first="Leslie S." last="Hemenway">Leslie S. Hemenway</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Harbor-UCLA Medical Center. UCLA Center for Vaccine Research, Torrance, and Kaiser Permanente Southern California Region, Regional Laboratories, North Hollywood</wicri:cityArea></affiliation></author><author><name sortKey="Greenberg, David P" sort="Greenberg, David P" uniqKey="Greenberg D" first="David P." last="Greenberg">David P. Greenberg</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Harbor-UCLA Medical Center. UCLA Center for Vaccine Research, Torrance, and Kaiser Permanente Southern California Region, Regional Laboratories, North Hollywood</wicri:cityArea></affiliation></author><author><name sortKey="Ward, Joel I" sort="Ward, Joel I" uniqKey="Ward J" first="Joel I." last="Ward">Joel I. Ward</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Harbor-UCLA Medical Center. UCLA Center for Vaccine Research, Torrance, and Kaiser Permanente Southern California Region, Regional Laboratories, North Hollywood</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published" when="1996-10">1996-10</date><biblScope unit="volume">174</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="752">752</biblScope><biblScope unit="page" to="759">759</biblScope></imprint><idno type="ISSN">0022-1899</idno></series><idno type="istex">4F59A0F00B3C40BCEDAF488D3CE7AF21301D2DFF</idno><idno type="DOI">10.1093/infdis/174.4.752</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Population-based prospective surveillance of invasive pneumococcal disease was done in Southern California from 31 March 1992 to 1 April 1995; 814 cases were identified, for an incidence of 12.5/100,000 persons/year. The incidence among persons ≤2, ≤5, and ≥65 years of age was 145, 72, and 32/100,000, respectively. More than 95% of cases included bacteremia; incidence of meningitis was 0.8/100,000. Among children ≤2 years of age, 79% of isolates were obtained in the outpatient setting, compared with 16% of isolates among persons ≥15 years of age. Eighty percent of isolates were serotypes included in heptavalent pneumococcal conjugate vaccines currently being evaluated. Children ≤2 years of age were at highest risk of having an isolate resistant to penicillin. Among resistant isolates, high-level resistance increased from 4% to 21% over a 3-year period. Prospective epidemiologic data are needed to perform a protective efficacy trial of pneumococcal conjugate vaccines in infants, among whom most invasive pneumococcal disease is vaccine-preventable.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Zangwill, Kenneth M" sort="Zangwill, Kenneth M" uniqKey="Zangwill K" first="Kenneth M." last="Zangwill">Kenneth M. Zangwill</name></region><name sortKey="Greenberg, David P" sort="Greenberg, David P" uniqKey="Greenberg D" first="David P." last="Greenberg">David P. Greenberg</name><name sortKey="Hemenway, Leslie S" sort="Hemenway, Leslie S" uniqKey="Hemenway L" first="Leslie S." last="Hemenway">Leslie S. Hemenway</name><name sortKey="Vadheim, Constance M" sort="Vadheim, Constance M" uniqKey="Vadheim C" first="Constance M." last="Vadheim">Constance M. Vadheim</name><name sortKey="Vannier, Ann M" sort="Vannier, Ann M" uniqKey="Vannier A" first="Ann M." last="Vannier">Ann M. Vannier</name><name sortKey="Ward, Joel I" sort="Ward, Joel I" uniqKey="Ward J" first="Joel I." last="Ward">Joel I. Ward</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002099 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002099 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4F59A0F00B3C40BCEDAF488D3CE7AF21301D2DFF
|texte= Epidemiology of Invasive Pneumococcal Disease in Southern California: Implications for the Design and Conduct of a Pneumococcal Conjugate Vaccine Efficacy Trial
}}
| This area was generated with Dilib version V0.6.23. |  |